NRSN

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forwardCAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape for ALS, persistent unmet medical needs, and emerging th

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALSTDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progressionPrimeC demonstrates target engagement with consistent effects across clinical outcomes, survival, and biomarkers, supporting its potential as a disease-modifying therapyCAMBRIDGE, Mass., June 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its Phase 2b

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued development of PrimeC's multi-target approach in Alzheimer's diseaseCAMBRIDGE, Mass., June 25, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive biomarker findings from its Phase 2, randomized, double-blind, placebo-controlled proof-of-concept RoAD study (NST-AD-001) of PrimeC in Alzheimer's disease (AD). The RoAD c

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that EverythingALS will host a conversation built around a look at emerging data on PrimeC and what it may mean for the science of ALS and the people living with it. Event details:Date: June 24, 2026Time: 7 pm ETLink for registration: Click HereThe session will be presented by Prof. Jeffrey Rosenfeld, MD, PhD, FAAN, Professor of Neurology and Director of the Neuromuscular ALS/MND Program at Loma Linda University School of Medicine. With more than

4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALSExpands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United StatesFurther strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeCCAMBRIDGE, Mass., June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued Korean

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The patent, entitled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholderCAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with certain investors to purchase $600,000 of ordinary shares in a private placement. In connection with the offering, NeuroSense agreed to sell an aggregate of 750,000 ordinary shares at a price of $0.80 per share, representing a purchase price of 6.7% above the closing pricing of NeuroSense's ordinary

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

Patent Protection Through October 2042Follows prior patent grants in the U.S. and AustraliaFurther strengthens NeuroSense's global intellectual property portfolioCAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled "Compositions Comprising Ciprofloxacin and Celecoxib."   The granted Brazilian patent, following prior approval of the corresponding U.S. patent (12,097,185) and Australian

Notifications have no immediate effect on the listing or trading of the Company's securities on NasdaqNasdaq has provided the Company until September 29, 2026 to regain compliance with both requirementsThe Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder valueCAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today announced that it received two notification letters from the Listing Qualifications Department of

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)

20-F - NeuroSense Therapeutics Ltd. (0001875091) (Filer)